Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) hosted anInvestor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior management team provided an overview of the company's business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A copy of the presentation and a replay of the webcast are available at investor.ligand.com.
Business Model: Management reviewed Ligand's differentiated strategy, unique market position and business model, which is focused on investing in late-clinical stage assets and maintaining and licensing the company's Captisol® technology platform to generate royalties and revenues for shareholders.
Investment Process: Management provided an overview of Ligand's investment criteria and due diligence process to source assets with superior risk-reward profiles.
Restructuring of Business: Management highlighted several key 2023 developments stemming from the company's decision to focus on a lean infrastructure and high-margin business:
Late-Stage Assets: Management highlighted a selection of the most advanced late-stage assets in its portfolio and reviewed seven potential major pipeline events expected in 2024, including:
Portfolio Highlights: Management highlighted the development status and market opportunity for select commercial stage and pipeline programs including Travere Therapeutics' FILSPARI™, Verona Pharma's ensifentrine, and our berdazimer gel.
Recent Transactions: Management discussed the recent soticlestat and TZIELD (teplizumab) royalty acquisitions, which closed in Q4 2023.
Captisol Technology Platform: Management shared that Captisol continues to enable product approvals for Ligand partners, with five possible approvals anticipated in 2024.
2024 Investment Outlook: Management highlighted thatLigand's Q4 2023 pipeline has over 20 actionable opportunities representing more than $1 billion in potential investments. The company believes it is well positioned and resourced to close multiple new investments in 2024, depending on the size and quality of the opportunities.
The company introduced 2024 financial guidance, as follows:
Posted In: LGND